AR069611A1 - Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma - Google Patents

Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma

Info

Publication number
AR069611A1
AR069611A1 ARP080105336A ARP080105336A AR069611A1 AR 069611 A1 AR069611 A1 AR 069611A1 AR P080105336 A ARP080105336 A AR P080105336A AR P080105336 A ARP080105336 A AR P080105336A AR 069611 A1 AR069611 A1 AR 069611A1
Authority
AR
Argentina
Prior art keywords
disorders
congestion
pharmaceutical compositions
same
allergy
Prior art date
Application number
ARP080105336A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR069611A1 publication Critical patent/AR069611A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a la sal tosilato de trans-N-isobutil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)-fenil]-ciclobutanocarboxamida de formula (1) a solvatos (por ejemplo, hidratos) de la misma, a polimorfos de la misma, a composiciones farmacéuticas de la misma y a un procedimiento para tratar depresion, trastornos del humor, esquizofrenia, trastornos de ansiedad, trastornos cognitivos, enfermedad de Alzheimer, trastorno por déficit de atencion (TDA), trastorno por déficit de atencion con hiperactividad (TDAH), trastornos psicoticos, trastornos del sueno, obesidad, mareo, epilepsia, mareo por movimiento, enfermedades respiratorias, alergia, respuestas de las vías respiratorias inducidas por alergia, rinitis alérgica, congestion nasal, congestion alérgica, congestion, hipotension, enfermedad cardiovascular, enfermedades del tracto GI, hiper e hipomotilidad y secrecion ácida del tracto gastrointestinal que comprende administrar una cantidad terapéuticamente eficaz de la misma. Reivindicacion 2: Una sal tosilato de un compuesto de formula (1).
ARP080105336A 2007-12-07 2008-12-09 Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma AR069611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US569607P 2007-12-07 2007-12-07

Publications (1)

Publication Number Publication Date
AR069611A1 true AR069611A1 (es) 2010-02-03

Family

ID=40380628

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105336A AR069611A1 (es) 2007-12-07 2008-12-09 Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma

Country Status (15)

Country Link
US (1) US8178574B2 (es)
EP (1) EP2231630B1 (es)
JP (1) JP4566259B2 (es)
KR (1) KR20100075679A (es)
CN (1) CN101939306A (es)
AR (1) AR069611A1 (es)
AU (1) AU2008332880C1 (es)
CA (1) CA2708043C (es)
IL (1) IL205963A0 (es)
MX (1) MX2010006162A (es)
NZ (1) NZ585671A (es)
RU (1) RU2451016C2 (es)
TW (1) TW200932213A (es)
WO (1) WO2009071988A1 (es)
ZA (1) ZA201004768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2124933T3 (da) 2007-01-22 2012-11-19 Pfizer Prod Inc Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69307875T2 (de) * 1992-04-10 1997-05-22 Pfizer Acylaminoindolderivate als 5-ht1 agonisten
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
DK2124933T3 (da) * 2007-01-22 2012-11-19 Pfizer Prod Inc Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf

Also Published As

Publication number Publication date
MX2010006162A (es) 2010-06-25
ZA201004768B (en) 2011-03-30
TW200932213A (en) 2009-08-01
KR20100075679A (ko) 2010-07-02
EP2231630A1 (en) 2010-09-29
AU2008332880B2 (en) 2012-01-19
NZ585671A (en) 2012-06-29
EP2231630B1 (en) 2012-11-07
CA2708043C (en) 2012-11-13
CA2708043A1 (en) 2009-06-11
JP2009161517A (ja) 2009-07-23
WO2009071988A1 (en) 2009-06-11
JP4566259B2 (ja) 2010-10-20
RU2010122972A (ru) 2011-12-10
CN101939306A (zh) 2011-01-05
US20100256213A1 (en) 2010-10-07
US8178574B2 (en) 2012-05-15
AU2008332880A1 (en) 2009-06-11
RU2451016C2 (ru) 2012-05-20
AU2008332880C1 (en) 2012-07-19
IL205963A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
AR064963A1 (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma
UY29882A1 (es) Antagonistas del receptor 3 de la histamina
DE602006018301D1 (de) Histamin-3-rezeptorantagonisten
WO2007105053A3 (en) Tetralines antagonists of the h-3 receptor
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
CL2008001982A1 (es) Acido (2s)-2-{[3´-cloro-4´-[2,2-dimetilpirrolidin-1-il) carbonil]-5-fluorobifenil-2-il]oxi}propanoico y su sal 2-metilpropan-2-amina; formas cristalinas de la sal y del acido libre; compuestos intermediarios; y uso en el tratamiento de asma, rinitis y enfermedad pulmonar obstructiva cronica.
BRPI0507374A (pt) moduladores do receptor de histamina-3
DE502005010170D1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
ECSP10010156A (es) Piperidino-dihidrotienopirimidinas sustituidas
AR069611A1 (es) Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma
NI200700084A (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
MX2011011477A (es) Derivados de isoxazol-piridazina.
PL2081910T3 (pl) Nowe związki
AR065477A1 (es) Diaminopirimidinas
BRPI0516079A (pt) antagonistas de receptor de histamina-3
US20220281846A1 (en) Compounds and compositions for the treatment of respiratory diseases
BRPI0514820A (pt) antagonistas de receptor de histamina-3 amina azabicìclicos
BR112013031759A2 (pt) forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides
CY1113762T1 (el) Τοσυλικο αλας μιας θεραπευτικης ενωσης και φαρμακευτικες συνθεσεις αυτου
CY1114789T1 (el) Ανταγωνιστες υποδοχεα ισταμινης-3
ATE396716T1 (de) Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
CU20070070A7 (es) Composición farmacéutica de agomelatina
TH98489A (th) ไพแรซอลแอนะล็อก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal